doi: 10.1161/hq1201.100225
© 2001 American Heart Association, Inc.
Thrombosis |
Vascular Outcome in Patients With Homocystinuria due to Cystathionine ß-Synthase Deficiency Treated Chronically
A Multicenter Observational Study
From the National Center for Inherited Metabolic Disorders (S.Y., P.M.H., E.R.N.), The Children’s Hospital, Dublin, Ireland; Department of General Internal Medicine (G.H.J.B.), University Hospital Nijmegen, The Netherlands; The Children’s Hospital at Westmead (B.W.), Sydney, Australia; University of New South Wales (D.E.L.W.), Department of Cardiovascular Medicine, Prince of Wales Hospital, Randwick, Sydney, Australia; Postgraduate Center (D.P.B.), Middlesex Hospital, London, UK; The National Hospital for Neurology and Neurosurgery (P.J.L.), London, UK; and Willink Biochemical Genetics Unit (J.H.W.), Royal Manchester Children’s Hospital, Manchester, UK.
Correspondence to Eileen R. Naughten. National Center for Inherited Metabolic Disorders, The Children’s Hospital, Temple Street, Dublin 1, Ireland. E-mail tchmeta{at}indigo.ie
An inborn error of metabolism, homocystinuria due to cystathionine ß-synthase deficiency, results in markedly elevated levels of circulating homocysteine. Premature vascular events are the main life-threatening complication. Half of all untreated patients have a vascular event by 30 years of age. We performed a multicenter observational study to assess the effectiveness of long-term homocysteine-lowering treatment in reducing vascular risk in 158 patients. Vascular outcomes were analyzed and effectiveness of treatment in reducing vascular risk was evaluated by comparison of actual to predicted number of vascular events, with the use of historical controls from a landmark study of 629 untreated patients with cystathionine ß-synthase deficiency. The 158 patients had a mean (range) age of 29.4 (4.5 to 70) years; 57 (36%) were more than 30 years old, and 10 (6%) were older than 50 years. There were 2822 patient-years of treatment, with an average of 17.9 years per patient. Plasma homocysteine levels were markedly reduced from pretreatment levels but usually remained moderately elevated. There were 17 vascular events in 12 patients at a mean (range) age of 42.5 (18 to 67) years: pulmonary embolism (n=3), myocardial infarction (n=2), deep venous thrombosis (n=5), cerebrovascular accident (n=3), transient ischemic attack (n=1), sagittal sinus thrombosis (n=1), and abdominal aortic aneurysm (n=2). Without treatment, 112 vascular events would have been expected, for a relative risk of 0.09 (95% CI 0.036 to 0.228; P<0.0001). Treatment regimens designed to lower plasma homocysteine significantly reduce cardiovascular risk in cystathionine ß-synthase deficiency despite imperfect biochemical control. These findings may be relevant to the significance of mild hyperhomocysteinemia that is commonly found in patients with vascular disease.
Key Words: homocysteine • cardiovascular disease • cystathionine beta-synthase deficiency • risk factors
This article has been cited by other articles:
 |
|
 |
|
  S. Dayal and S. R. Lentz Murine Models of Hyperhomocysteinemia and Their Vascular Phenotypes Arterioscler. Thromb. Vasc. Biol., September 1, 2008; 28(9): 1596 - 1605. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J Moat Plasma total homocysteine: instigator or indicator of cardiovascular disease? Ann Clin Biochem, July 1, 2008; 45(4): 345 - 348. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. N. Rodionov and S. R. Lentz The Homocysteine Paradox Arterioscler. Thromb. Vasc. Biol., June 1, 2008; 28(6): 1031 - 1033. [Full Text] [PDF]
|
|
|
|
 |
|
 G. Hron, R. Lombardi, S. Eichinger, A. Lecchi, P. A. Kyrle, and M. Cattaneo Low vitamin B6 levels and the risk of recurrent venous thromboembolism Haematologica, September 1, 2007; 92(9): 1250 - 1253. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Francis, S. Raghunathan, and P. Khanna The role of genetics in stroke Postgrad. Med. J., September 1, 2007; 83(983): 590 - 595. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. G. Ray, C. Kearon, Q. Yi, P. Sheridan, E. Lonn, and for the Heart Outcomes Prevention Evaluation 2 (HO Homocysteine-Lowering Therapy and Risk for Venous Thromboembolism: A Randomized Trial Ann Intern Med, June 5, 2007; 146(11): 761 - 767. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Chwatko, G. H. J. Boers, K. A. Strauss, D. M. Shih, and H. Jakubowski Mutations in methylenetetrahydrofolate reductase or cystathionine {beta}-syntase gene, or a high-methionine diet, increase homocysteine thiolactone levels in humans and mice FASEB J, June 1, 2007; 21(8): 1707 - 1713. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q. H. Meng, G. Yang, W. Yang, B. Jiang, L. Wu, and R. Wang Protective Effect of Hydrogen Sulfide on Balloon Injury-Induced Neointima Hyperplasia in Rat Carotid Arteries Am. J. Pathol., April 1, 2007; 170(4): 1406 - 1414. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Colgan and R. C. Austin Homocysteinylation of Metallothionein Impairs Intracellular Redox Homeostasis: The Enemy Within! Arterioscler. Thromb. Vasc. Biol., January 1, 2007; 27(1): 8 - 11. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Dayal, K. M. Wilson, L. Leo, E. Arning, T. Bottiglieri, and S. R. Lentz Enhanced susceptibility to arterial thrombosis in a murine model of hyperhomocysteinemia Blood, October 1, 2006; 108(7): 2237 - 2243. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Refsum, E. Nurk, A. D. Smith, P. M. Ueland, C. G. Gjesdal, I. Bjelland, A. Tverdal, G. S. Tell, O. Nygard, and S. E. Vollset The Hordaland Homocysteine Study: A Community-Based Study of Homocysteine, Its Determinants, and Associations with Disease J. Nutr., June 1, 2006; 136(6): 1731S - 1740S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Ganji and M. R. Kafai Population References for Plasma Total Homocysteine Concentrations for U.S. Children and Adolescents in the Post-Folic Acid Fortification Era J. Nutr., September 1, 2005; 135(9): 2253 - 2256. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. B. Kilicdag, T. Bagis, E. Tarim, E. Aslan, S. Erkanli, E. Simsek, B. Haydardedeoglu, and E. Kuscu Administration of B-group vitamins reduces circulating homocysteine in polycystic ovarian syndrome patients treated with metformin: a randomized trial Hum. Reprod., June 1, 2005; 20(6): 1521 - 1528. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. P. Riksen, G. A. Rongen, G. H.J. Boers, H. J. Blom, P. H.H. van den Broek, and P. Smits Enhanced Cellular Adenosine Uptake Limits Adenosine Receptor Stimulation in Patients With Hyperhomocysteinemia Arterioscler. Thromb. Vasc. Biol., January 1, 2005; 25(1): 109 - 114. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Refsum, A. W. Grindflek, P. M. Ueland, A. Fredriksen, K. Meyer, A. Ulvik, A. B. Guttormsen, O. E. Iversen, J. Schneede, and B. F. Kase Screening for Serum Total Homocysteine in Newborn Children Clin. Chem., October 1, 2004; 50(10): 1769 - 1784. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Moat, S. N. Doshi, D. Lang, I. F. W. McDowell, M. J. Lewis, and J. Goodfellow Treatment of coronary heart disease with folic acid: is there a future? Am J Physiol Heart Circ Physiol, July 1, 2004; 287(1): H1 - H7. [Full Text] [PDF]
|
|
|
|
|
|
H. Refsum, A. D. Smith, P. M. Ueland, E. Nexo, R. Clarke, J. McPartlin, C. Johnston, F. Engbaek, J. Schneede, C. McPartlin, et al. Facts and Recommendations about Total Homocysteine Determinations: An Expert Opinion Clin. Chem., January 1, 2004; 50(1): 3 - 32. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D.E.L. Wilcken Homocysteine, smoking and vascular disease Eur. Heart J., October 2, 2002; 23(20): 1559 - 1560. [Full Text] [PDF]
|
|
|
|
 |
|
 N. Weiss, C. Keller, U. Hoffmann, and J. Loscalzo Endothelial dysfunction and atherothrombosis in mild hyperhomocysteinemia Vascular Medicine, August 1, 2002; 7(3): 227 - 239. [Abstract] [PDF]
|
|